. Author manuscript; available in PMC: 2022 Sep 1.

Published in final edited form as: Toxicol In Vitro. 2022 May 23;83:105396. doi: 10.1016/j.tiv.2022.105396

Table 4:

Pathways altered by PCB126 treatment of preadipocytes at the 3-Day timepoint (top 25, Fdr<0.05).

Pathway	pv_fdr
Cytokine-cytokine receptor interaction	3.69E-06
Viral protein interaction with cytokine and cytokine receptor	4.52E-06
MAPK signaling pathway	1.1E-05
Osteoclast differentiation	7.33E-05
Neuroactive ligand-receptor interaction	7.33E-05
AGE-RAGE signaling pathway in diabetic complications	0.000132
Human papillomavirus infection	0.000132
Pathways in cancer	0.000177
Ras signaling pathway	0.000197
Complement and coagulation cascades	0.000197
Cell adhesion molecules	0.000197
Hypertrophic cardiomyopathy	0.000197
ECM-receptor interaction	0.000197
PI3K-Akt signaling pathway	0.000197
Calcium signaling pathway	0.000197
Rheumatoid arthritis	0.000214
Small cell lung cancer	0.000337
TNF signaling pathway	0.000337
Axon guidance	0.000337
Renin secretion	0.000461
IL-17 signaling pathway	0.000501
Focal adhesion	0.000518
NF-kappa B signaling pathway	0.000553
Amoebiasis	0.00062
Chemokine signaling pathway	0.00067